Personalis PE Ratio 2018-2023 | PSNL
Current and historical p/e ratio for Personalis (PSNL) from 2018 to 2023. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Personalis PE ratio as of April 23, 2024 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Personalis PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2024-04-24 |
1.30 |
|
0.00 |
| 2023-12-31 |
2.10 |
$-2.40 |
0.00 |
| 2023-03-31 |
2.76 |
$-2.46 |
0.00 |
| 2022-12-31 |
1.98 |
$-2.48 |
0.00 |
| 2022-09-30 |
2.97 |
$-2.26 |
0.00 |
| 2022-06-30 |
3.45 |
$-1.97 |
0.00 |
| 2022-03-31 |
8.19 |
$-1.71 |
0.00 |
| 2021-12-31 |
14.27 |
$-1.35 |
0.00 |
| 2021-03-31 |
24.61 |
$-1.19 |
0.00 |
| 2020-12-31 |
36.61 |
$-1.19 |
0.00 |
| 2020-09-30 |
21.67 |
$-1.06 |
0.00 |
| 2020-06-30 |
12.97 |
$-1.01 |
0.00 |
| 2020-03-31 |
8.07 |
$-1.61 |
0.00 |
| 2019-12-31 |
10.90 |
$-1.92 |
0.00 |
| 2019-09-30 |
14.68 |
$-2.21 |
0.00 |
| 2019-06-30 |
27.15 |
$-2.39 |
0.00 |
| 2023-09-30 |
1.21 |
$-1.84 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.070B |
$0.073B |
|
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
|
